Skip to main
OCUL
OCUL logo

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

Ocular Therapeutix (OCUL) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 47%
Buy 47%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Ocular Therapeutix Inc. has a promising outlook due to its consistent annual revenue growth from Dextenza since its launch in July 2019, indicating strong market acceptance and demand for its products. The company's proprietary hydrogel platform technology shows significant improvements in eye conditions, with positive clinical trial results for Axpaxli expected to further boost its market potential. Additionally, the anti-VEGF treatment class is projected to grow at a CAGR of 8%-10% through 2028, positioning Ocular to benefit from this expanding market as it captures established market share forecasts.

Bears say

Ocular Therapeutix has experienced a significant decline in sales, reporting a 68% year-over-year decrease attributed to market share erosion from competitors such as Eylea and Vabysmo, alongside pressure from newly introduced biosimilars. While Dextenza's revenue for the fourth quarter of 2024 met the company’s guidance at $17 million, it fell slightly short of consensus estimates, indicating challenges in maintaining growth within its portfolio. Additionally, the delay of pivotal data for the promising candidate Axpaxli to early 2026 raises concerns about the company's future prospects, escalating the risk associated with its ongoing clinical trials and overall valuation.

Ocular Therapeutix (OCUL) has been analyzed by 19 analysts, with a consensus rating of Buy. 47% of analysts recommend a Strong Buy, 47% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocular Therapeutix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocular Therapeutix (OCUL) Forecast

Analysts have given Ocular Therapeutix (OCUL) a Buy based on their latest research and market trends.

According to 19 analysts, Ocular Therapeutix (OCUL) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocular Therapeutix (OCUL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.